IGI Laboratories, Inc. Announces Eleventh Abbreviated New Drug Application Submission

IGI Laboratories, Inc. (NYSE: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its third abbreviated new drug application (ANDA) in 2013 to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions to eleven. Jason Grenfell-Gardner, President and CEO of the Company, commented, "Today's submission brings our total number of abbreviated new drug applications on file with the FDA to eleven which together we believe have a combined addressable market of approximately $250 million based on recent IMS. Our research and development team remains on track to deliver on our expectation to file at least six ANDAs in 2013. We believe that our development pipeline is the strongest organic driver we have to create long term value for our shareholders, and we plan to continue to invest in our research and development efforts to accelerate the growth of our pipeline. We remain focused on the development of topical generic pharmaceutical products and are optimistic about the opportunities in these markets.” About IGI Laboratories, Inc. IGI Laboratories is a generic topical pharmaceutical company. We develop and manufacture topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market.